[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-339753-105":59,"doc-detail-339753-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","lipocalin-2-as-a-prognostic-biomarker-and-its-association-with-systemic-inflammation-in-small-cell-lung-cancer","Lipocalin-2 as a prognostic biomarker and its association with systemic inflammation in small cell lung cancer","","Systemic inflammation is considered to influence small cell lung cancer (SCLC) progression, yet the precise connection remains unclear. This study evaluates Lipocalin-2, an inflammation-associated biomarker, to determine its prognostic relevance in SCLC and its interplay with other markers. A retrospective cohort of 191 SCLC patients receiving platinum-based chemotherapy is analyzed using immunohistochemistry, time-dependent ROC-derived cutoffs for Lipocalin-2 and NLR, and sarcopenia assessment via the pectoralis muscle index.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/lipocalin-2-as-a-prognostic-biomarker-and-its-association-with-systemic-inflammation-in-small-cell-lung-cancer/339753/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/lipocalin-2-as-a-prognostic-biomarker-and-its-association-with-systemic-inflammation-in-small-cell-lung-cancer/339753.png","ImageObject",300,407,{"name":92,"@type":93},"Liam","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the main aim of this study on Lipocalin-2 in SCLC?","Question",{"text":112,"@type":113},"To determine whether Lipocalin-2 has prognostic value in small cell lung cancer and to evaluate its relationship with systemic inflammation-related markers such as NLR and the sarcopenia-related pectoralis muscle index.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were Lipocalin-2 and neutrophil-to-lymphocyte ratio (NLR) measured and classified?",{"text":117,"@type":113},"Lipocalin-2 expression was assessed using immunohistochemistry, and optimal cutoff values for Lipocalin-2 and NLR were derived using time-dependent receiver operating characteristic curve analysis.",{"name":119,"@type":110,"acceptedAnswer":120},"What prognostic associations were reported for Lipocalin-2 in limited-stage SCLC?",{"text":121,"@type":113},"High Lipocalin-2 expression was linked to worse progression-free survival and overall survival, and it was associated with lower complete response rates. No significant prognostic implications were found in extensive-stage SCLC.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},339753,1790572544,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":52,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":144,"preview_page_count":19,"preview_urls":145},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","DOI: 10.1111/1759-7714.15389  \nORIGINA L ARTICLE  \nLipocalin-2 as a prognostic biomarker and its association with systemic inflammation in small cell lung cancer  \nSe-Il Go 1,2,3  | Jung Wook Yang 3,4,5 | Woo Je Lee 6 | Eun Jeong Jeong 6 | Sungwoo Park 2,3,6 | Gyeong-Won Lee 2,3,6   \n1Department of Internal Medicine, Gyeongsang National University Changwon Hospital, Changwon, Korea  \n2Department of Internal Medicine, Gyeongsang National University College of Medicine, Jinju, Korea  \n3Institute of Medical Science, Gyeongsang National University, Jinju, Korea 4Department of Pathology, Gyeongsang National University Hospital, Jinju, Korea  \n5Department of Pathology, Gyeongsang National University College of Medicine, Jinju, Korea 6Division of Hematology and Oncology, Department of Internal Medicine, Gyeongsang National University Hospital, Jinju, Korea  \nCorrespondence  \nGyeong-Won Lee, Division of Hematology and Oncology, Department of Internal Medicine, Gyeongsang National University Hospital,  \nGyeongsang National University College of Medicine, 79 Gangnam-ro, Jinju, Korea. [Email:](Email: brightree24@gmail.com)[ brightree24@gmail.com](Email: brightree24@gmail.com)  \nFunding information  \nBasic Science Research Program through the National Research Foundation of Korea, Grant/Award Number: RS-2023-00219399  \nAbstract  \nBackground: Systemic inflammation is believed to contribute to small cell lung cancer (SCLC) progression, but the underlying relationship remains unclear. Lipocalin-2, a potential biomarker of inflammation, has been implicated in various cancers but its prognostic value in SCLC is underexplored.  \nMethods: We retrospectively analyzed 191 patients with SCLC (72 with limited-stage [LD] and 119 with extensive-stage) treated using platinum-based chemotherapy. Lipocalin-2 expression was evaluated using immunohistochemistry. Optimal cutoff values for lipocalin-2 and neutrophil-to-lymphocyte ratio (NLR) were determined using time-dependent receiver operating characteristic curve analysis. The pectoralis muscle index was used to assess sarcopenia.  \nResults: In LD-SCLC, high lipocalin-2 expression was associated with worse progression-free survival (PFS; median: 7.0 vs. 15.9 months, p = 0.015) and overall survival (OS; median: 12.9 vs. 30.3 months, p = 0.035) compared with low lipocalin-2 expression. Patients were stratified into three prognostic groups by combining lipocalin-2 with NLR: low lipocalin-2/low NLR, high lipocalin-2/low NLR or low lipocalin-2/high NLR, and high lipocalin-2/high NLR (median PFS: 17.3 vs. 11.0 vs. 6.3 months, p = 0.004; median OS: 30.5 vs. 17.3 vs. 8.6 months, p = 0.002) . Similar trends were observed when combining lipocalin-2 with the pectoralis muscle index. High lipocalin-2 expression was also associated with lower complete response rates (18.9% vs. 34.3%, p = 0.035) . No significant prognostic implications were found forlipocalin-2 in extensive-stage SCLC.  \nConclusions: High lipocalin-2 expression is potentially associated with poorer survival in LD-SCLC. Combining lipocalin-2 with other inflammation-related markers could improve prognostic stratification.  \nKEYW ORD S  \nbiomarkers, inflammation, lipocalin-2, sarcopenia, small cell lung carcinoma  \nINTRODUCTION  \nSmall cell lung cancer (SCLC) is a rapidly progressing malignancy with a poor prognosis.1 Smoking, the primary risk factor for SCLC, introduces carcinogenic compounds in the body and triggers systemic inflammation, which may contribute to cancer progression. 1,2 Recent studies  \nSe-Il Go and Jung Wook Yang contributed equally to this study.  \nsuggested the clinical relevance of inflammatory markers in SCLC, including the neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio, systemic immuneinflammation index, and skeletal muscle index (SMI), which is associated with sarcopenia.3–6 However, direct experimental evidence supporting the relationship between systemic inflammation and SCLC progression is limited, possibly","cbCaik98vNap5nM7","https://ap.wps.com/l/cbCaik98vNap5nM7","pdf",1764227,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Rationale for systemic inflammation and inflammatory markers\n# Methods\n## Patient selection","[{\"question\":\"What is the main aim of this study on Lipocalin-2 in SCLC?\",\"answer\":\"To determine whether Lipocalin-2 has prognostic value in small cell lung cancer and to evaluate its relationship with systemic inflammation-related markers such as NLR and the sarcopenia-related pectoralis muscle index.\"},{\"question\":\"How were Lipocalin-2 and neutrophil-to-lymphocyte ratio (NLR) measured and classified?\",\"answer\":\"Lipocalin-2 expression was assessed using immunohistochemistry, and optimal cutoff values for Lipocalin-2 and NLR were derived using time-dependent receiver operating characteristic curve analysis.\"},{\"question\":\"What prognostic associations were reported for Lipocalin-2 in limited-stage SCLC?\",\"answer\":\"High Lipocalin-2 expression was linked to worse progression-free survival and overall survival, and it was associated with lower complete response rates. No significant prognostic implications were found in extensive-stage SCLC.\"}]","Lipocalin-2 as a prognostic biomarker and its association with systemic inflammation in small cell lung cancer | PDF",1790032005,25,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/055a446906762507b9acd97e2575564c.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ec240948bcfa54dcca41e372362e063d.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/065045f2d4538323ffd6f60d1417a1ad.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/07a29a20bf26ddc83120e818ec4b5dcd.webp",980,1287]